Modified anticancer drug can simultaneously target tumor sites and show whether or not it is working

July 30, 2014
Modified anticancer drug can simultaneously target tumor sites and show whether or not it is working
A modified platinum-based prodrug targets cancer cells and triggers cell death, or apoptosis, causing apoptosis sensors to fluoresce green. Credit: Ugreen/iStock/Thinkstock

Cancer drugs can be modified to specifically target tumor sites to help personalize cancer treatment. And while it is relatively easy to determine if the drugs have been delivered to the correct location, it is more difficult to monitor their therapeutic success. Now, a team led by Bin Liu from the A*STAR Institute of Materials Research and Engineering in Singapore, in collaboration with Ben Zhong Tang at Hong Kong University of Science and Technology, has developed an anticancer drug with an inbuilt mechanism that shows if it is working.

Platinum-based drugs are effective against many cancers, killing cells by triggering cellular suicide, or apoptosis. These drugs can, however, have severe side effects. Nontoxic forms can be modified, as a type of prodrug, to convert to their toxic form only after entering the targeted , so as not to harm noncancerous cells.

Liu and colleagues went one step further by modifying a platinum-based prodrug to not only target tumor cells effectively, but also show whether or not it was having the desired effect. According to Liu, this added feature could be crucial for improving treatment.

"Early evaluation of a patient's response to a specific cancer therapy is important in clinical applications because it can minimize the duration of ineffective courses," explains Liu. "The effectiveness of is commonly evaluated using to measure the tumor size, but this is unsatisfactory as the change in size is not obvious at the early stages of therapy."

In their new system, Liu and her team included an apoptosis sensor that is released when the prodrug converts to its toxic form inside the targeted tumor cells. The toxic form triggers cell apoptosis and activates an enzyme called caspase 3, which then cleaves the apoptosis sensor and causes it to fluoresce green. This provides a visual signal that the drug is killing the cells.

Liu and her colleagues tested the mechanism by treating cultured with the modified platinum prodrug. They observed a gradual increase in fluorescence in the cancer cells, reaching a maximum level of fluorescence six hours after treatment. Noncancerous cells were not affected in the same way, further proving the effectiveness of their targeting mechanism.

Such noninvasive and real-time imaging of drug-induced apoptosis could be used to evaluate the therapeutic response to a specific at an early stage, explains Liu. "Our system can simultaneously deliver the therapeutic drugs and noninvasively evaluate the therapeutic responses in situ."

Explore further: Stem cell researcher targets the 'seeds' of breast cancer metastasis

More information: Yuan, Y., Kwok, R. T. K., Tang, B. Z., Liu, B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. Journal of the American Chemical Society 136, 2546–2554 (2014). DOI: 10.1021/ja411811w

Related Stories

Stem cell researcher targets the 'seeds' of breast cancer metastasis

July 11, 2014
For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical ...

Targeted toxin active in platinum-resistant ovarian cancers

April 6, 2013
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

mrdingdong
not rated yet Jul 30, 2014
What next? When is it coming in the market? And does it have a name?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.